definiens: as that term is defined in the Private SecuritiesLitigation Reform Act of 1995 regarding the research, development and commercialization ofpharmaceutical products . Such forward - looking statements are based on current expectations andinvolve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations . No forward - looking statement can be guaranteed . Among other risks, there can be no guarantee that nivolumab willreceive regulatory approval in the U.S. either as a single agent or in a combination regimen, or, ifapproved, that it will become a commercially successful product . Forward - looking statements in thispress release should be evaluated together with the many uncertainties that affect Bristol - Myers Squibb'sbusiness, particularly those identified in the cautionary factors discussion in Bristol - Myers Squibb'sAnnual Report on Form 10 - K for the year ended December 31, 2013 in our Quarterly Reports on Form10 - Q and our Current Reports on Form 8 - K. Bristol - Myers Squibb undertakes no obligation to publiclyupdate any forward - looking statement, whether as a result of new information, future events or otherwise